CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 13, 2016
Result type: Reports
Project Number: SR0503-000
Product Line: Reimbursement Review

Generic Name: sarilumab

Brand Name: Kevzara

Manufacturer: Sanofi Genzyme

Therapeutic Area: Arthritis, Rheumatoid

Indications: Arthritis, Rheumatoid

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 18, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions